Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

These are the world’s best airline rewards programs!

.. and 3 of the 5 winners use Loyal Solutions technology for the payment/card-linked part of their award winning programsWinner North America:Air Canada AeroplanWinner Middle East and Africa:Qatar Airways Privilege ClubWinner Asia Pacific:Cathay Pacific Asia Miles "This is just an incredibly proud day for all of us at Loyal Solutions. To witness 3 of our close partners being named the best program in their region is so gratifying and such a motivation for all of us. We understand that Loyal Solutions is only one part of the equation, but we are proud to have contributed in some

BioStock: BioInvent makes a strong entrance at ESMO in Barcelona

BioInvent has released additional positive preliminary efficacy data from its ongoing phase IIa dose expansion study of BI-1808 as a monotherapy. Additionally, BioInvent and Transgene are set to present encouraging initial phase I/IIa data on BT-001 at ESMO 2024. BI-1910 will also be featured in a poster presentation at the same conference.Read the article at biostock.se: https://www.biostock.se/en/2024/09/bioinvent-makes-a-strong-entrance-at-esmo-in-barcelona/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/

Glycorex Transplantation AB (GTAB B): Results from Norwegian platelet evaluation presented at conference

As previously announced, a blood bank in Norway has evaluated our transfusion product, Glycosorb® ABO (4 ml), for the preparation of low-titer blood group O platelet concentrate with positive results. The findings were recently presented at a national transfusion conference in Norway. Apheresis platelet concentrate from blood group O contains anti-A/B antibodies (blood group-specific antibodies) and can be transfused to recipients with blood group A, B, or AB, as long as the concentrate contains a low titer (level) of these anti-A/B antibodies. The method traditionally used to reduce

Brain+ is set to deliver on an ambitious UK commercial plan to reach recurring revenue of DKK 7-8 million by 2025 and DKK 25-27 million by 2027

Copenhagen, Denmark, 13 September 2024 - Brain+ A/S (Nasdaq First North: BRAINP) Summary: Brain+ is preparing for UK market release of its first product, the CST-Assistant, by end September 2024 to offer scalable Cognitive Stimulation Therapy (CST) and better serve the ~1 million people living with dementia in the UK. The release will take place against a backdrop of highly supportive UK market conditions, highlighted by strong political support, new Right Care guidelines, which specifically emphasize the benefits of CST in dementia care, and a recent audit of UK memory services

Allurity completes strategic acquisition of Lyvoc, continuing its European growth journey

Allurity proudly announces the strategic acquisition of Lyvoc, a premier cybersecurity integration partner renowned for its expertise in supporting its clients to accelerate and secure their digital transformation. This acquisition marks a significant milestone for Allurity, enhancing its market position and expanding its comprehensive cybersecurity offering.   Lyvoc, based in France, brings a wealth of knowledge and experience in Identity and Access Management (IAM), Cloud Security and Security Compliance Automation. With a dedicated team of more than 50 passionate cybersecurity

Notification of managers’ and closely related parties’ transactions with Dampskibsselskabet NORDEN A/S’ shares in connection with share buy-back program

ANNOUNCEMENT NO. 201 – 13 SEPTEMBER 2024   In connection with the announced share buy-back program in NORDEN, A/S Motortramp continuously sells shares pro rata and the market is to be informed accordingly – see the attached file and announcements nos. 171/24 and 173/24, respectively. Kind regards, Dampskibsselskabet NORDEN A/S   Martin Badsted CFO     For further information: Martin Badsted, Chief Financial Officer, tel.: +45 33 42 05 26, e-mail: mba@norden.com

Elkem ASA - Notice of an extraordinary general meeting 2024

Oslo, 13 September 2024 An extraordinary general meeting of Elkem ASA will be held on 8 October at 09:00 (Norwegian time) for the election of new board members and a new member to the nomination committee. The meeting will be conducted as a digital meeting on the Lumi AGM, and with utilisation of electronic voting for all attending shareholders. The full notice is attached, and all relevant documents can be found on www.elkem.com/investor/debt-and-share-information/annual-general-meeting/ This information is subject to the disclosure requirements pursuant to section 5-12 of the

New AI-powered PoC, built on AiQu, revolutionizes technical quality assessment

Mölndal                                                                                      2024-09-13 A major player in the Tech sector has invested in a Proof of Concept (PoC) that utilizes advanced AI technology for quality assessment. With the help of Aixia's proprietary AI platform AiQu, the company will automate and streamline processes for its production environment. which will generate a big step forward for technological innovation for the company. AiQu – the AI platform behind Aixia's successful concept around AI for Industry. The PoC is built on top of AiQu, an AI

Composition of Sitowise's Shareholders' Nomination Board

Sitowise Group Plc, Stock Exchange Release, 13 September 2024 at 10.15 a.m. (EEST) The following members have been appointed to Sitowise Group Plc's Shareholders' Nomination Board: · Jan Hummel, Paradigm Capital Value Fund SICAV, · Juhana Kallio, Intera Partners Oy, · Stian Runde, Protector Forsikring ASA, and · Eero Heliövaara, Chair of Sitowise Board of Directors. Representatives of the three largest shareholders are elected annually to Sitowise's shareholders' nomination committee. The company's three largest shareholders, according to the situation on the first

Brain+ A/S announces the exercise price for its warrants of series TO 4

Copenhagen, Denmark, 13 September 2024 – Brain+ A/S (Nasdaq First North: BRAINP) · The exercise price of the warrants of series TO 4 has been set at DKK 0.08 · The exercise period for the TO 4 warrants runs from 16 - 27 September 2024 · The warrants of series TO 4 are tradable on Nasdaq First North Growth Market with the last day of trading being 25 September 2024  Brain+ A/S (“Brain+” or “the Company”) completed a pre-emptive rights issue of units in June 2024. As part of the issue, a total of 65,496,978 warrants of series TO 4 were issued with each warrant giving the

Roc Oil Company Pty Limited announces a recommended cash offer to the shareholders of Tethys Oil AB

THIS ANNOUNCEMENT IS NOT AN OFFER, WHETHER DIRECTLY OR INDIRECTLY, IN AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA OR SWITZERLAND OR IN ANY OTHER JURISDICTION WHERE SUCH OFFER PURSUANT TO LEGISLATION AND REGULATIONS IN SUCH RELEVANT JURISDICTION WOULD BE PROHIBITED BY APPLICABLE LAW. SHAREHOLDERS NOT RESIDENT IN SWEDEN WHO WISH TO ACCEPT THE OFFER (AS DEFINED BELOW) MUST MAKE INQUIRIES CONCERNING APPLICABLE LEGISLATION AND POSSIBLE TAX CONSEQUENCES. SHAREHOLDERS SHOULD REFER TO THE OFFER RESTRICTIONS INCLUDED IN THE SECTION TITLED “IMPORTANT

#24-88 Decision by the Disciplinary Committee regarding Nischer Properties AB

As of September 13, 2024, Nordic Growth Market NGM AB’s disciplinary committee has found that Nischer Properties AB (“the Company”) has breached MAR article 17 and paragraphs 4.1.1, 4.1.3 in Rules for companies whose shares are listed on Nordic SME (“the Rulebook”) and therefore ordered the Company to pay a fine of 100 000 SEK in accordance with chapter 5 of the Rulebook. Please see the attached decision from NGM’s disciplinary committee.Information regarding the affected instrument:Listing name: Nischer PropertiesExchange symbol: NISISIN-code: SE0000308298Market-ID: NSME

NIB signs sustainability-linked loan with Kesko

The Nordic Investment Bank (NIB) and Finnish Kesko Oyj have signed a EUR 150 million 7-year loan linked to Kesko’s goal of reducing greenhouse gas emissions and food waste. The loan will support Kesko’s ambition to minimise the impact on the climate and nature through own operations and its value chain. The interest rate margin on the sustainability-linked loan is tied to three key performance indicators (KPIs). The agreed KPIs are part of Kesko’s wider sustainability strategy. “The trading sector has a significant impact on our everyday life and on the environment, and the industry’s

Kesko signs a sustainability-linked loan with the Nordic Investment Bank

Kesko has signed a €150 million 7-year sustainability-linked loan with the Nordic Investment Bank (NIB), where the interest rate margin is tied to the attainment of certain sustainability targets set for greenhouse gas emissions and food waste. At the end of June 2024, more than half of all Kesko loans were sustainability-linked.The new loan will support Kesko’s ambition to minimise impact on the climate and nature through its own operations and its value chain. The loan’s interest rate margin is tied to three key performance indicators (KPIs) aligned with sustainability targets that are

Altti Väisänen appointed as Kamux’s Director, Business Development

Kamux Corporation, Stock Exchange Release, 13.9.2024 at 9:30 Altti Väisänen appointed as Kamux’s Director, Business Development Altti Väisänen (40, M.Sc.Econ.) has been appointed Director, Business Development, Car Flow & Data, at Kamux Corporation and a member of the Group Management Team as of October 10, 2024. In his role, Väisänen is responsible for Kamux Group’s car-related presales processes as well as the company's strategy implementation and data activities. He will be based in Espoo, Finland, and report to CEO Tapio Pajuharju. Most recently Väisänen worked at the U.S.-

BioStock: AdjuTec Pharma to start phase I trial with APC148

Adjutec is set to start its phase I clinical trial for the enzyme inhibitor APC148, marking a significant milestone for the company. The trial begins September 18 with CTC in Uppsala and will focus on assessing the candidate’s safety. With this step, AdjuTec moves from years of preclinical research into clinical-stage development, targeting the global issue of antibiotic resistance.Read the full article at biostock.se : https://www.biostock.se/en/2024/09/adjutec-pharma-to-start-phase-i-trial-with-apc148/ This is a press release from BioStock - Connecting

Nomination Committee for HANZA AB's 2025 Annual General Meeting appointed

According to a decision at HANZA AB's most recent Annual General Meeting, a Nomination Committee of four members, including the Chairman of the Board, shall be appointed by the three largest shareholders or groups of shareholders in terms of voting rights. Since one of the main shareholders is also the Chairman of the Board, and thus already has a seat on the Nomination Committee, he has waived his right to nominate a member in favor of the fourth largest shareholder. The Nomination Committee for the 2025 AGM has now been appointed and consists of the following members: · Gerald

Notice of Investor Presentation

13 September 2024 Ashoka WhiteOak Emerging Markets Trust plc (the "Company") Notice of Investor Presentation Ashoka WhiteOak Emerging Markets Trust plc announces that the Company’s Investment Adviser, led by Prashant Khemka, will provide a live presentation via Investor Meet Company on Tuesday, 8 October 2024 at 10:00am BST. The presentation will provide existing and potential shareholders an opportunity to learn more about the Company’s investment philosophy and strategy, the portfolio holdings and its performance since listing in May 2023. The presentation is open to all

Careium revises full-year outlook due to infrastructure transition delays in the UK and Sweden

Careium, the European champion in technology enabled care, has revised its full-year growth outlook downward due to infrastructure transition delays affecting its business more than expected, and it has clarified its profit outlook, reaffirming an increase in EBIT for 2024. The delays stem from the UK’s announcement of a two-year extension in March 2024 for its transition from analogue to digital landlines. Similarly, Sweden extended its 2G and 3G infrastructure by an additional year, as announced in May 2024.New outlook:For the full year 2024, Careium expects an organic sales growth of

Moberg Pharma lowers expectations on primary endpoint in ongoing phase 3 trial following data in a subset of patients

Moberg Pharma AB (OMX: MOB) announces that the company has received information about clinical cure in a subset of patients in the ongoing North American Phase 3 study for MOB-015 against nail fungus. The number of patients who have achieved clinical cure in this blinded subset of patients is lower than the company's expectations, which necessitates that Moberg Pharma inform the market about this fact.The North American Phase 3 study is ongoing at 33 study centers in the US and Canada, including a total of 384 patients. The study constitutes an essential part of the clinical data required

Plant-derived secondary organic aerosols can act as mediators of plant-plant interactions

A new study published in Science reveals that plant-derived secondary organic aerosols (SOAs) can act as mediators of plant-plant interactions. This research was conducted through the cooperation of chemical ecologists, plant ecophysiologists and atmospheric physicists at the University of Eastern Finland. It is well known that plants release volatile organic compounds (VOCs) into the atmosphere when damaged by herbivores. These VOCs play a crucial role in plant-plant interactions, whereby undamaged plants may detect warning signals from their damaged neighbours and prepare their

Executive Vice President & General Counsel leaves Skanska

Skanska announces today that Caroline Fellenius Omnell, Executive Vice President & General Counsel, is leaving Skanska. Caroline has been with Skanska for eight years and has been a member of the Group Leadership Team since 2017. A recruitment process will be initiated to appoint a successor."I want to thank Caroline for her commitment, strategic insight and development of the Legal function across the Group.  Her expert legal guidance has been vital in our continued success in navigating complex market conditions and strongly contributed to driving value to the company. I wish her all the

Kesko’s sales in August

Kesko’s sales decreased by 0.7% in August, or by 3.9% in comparable terms.”Kesko’s sales in August decreased by 0.7%. Sales decreased in the grocery trade and car trade divisions. In the building and technical trade division, sales in building and home improvement trade increased as a result of the Davidsen acquisition. The number of delivery days was down by 1 year-on-year in Kespro and in building and technical trade, which impacted sales performance,” says Jorma Rauhala, Kesko’s President and CEO. Sales in the grocery trade division totalled €566.6 million in August, down by 1.9%.

There are no items matching the current filter
There are no more items matching the current filter
Back to top